Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Intravesical Docetaxel Formulation for the Treatment of Ta/T1 Stage Bladder Cancer

Funder: Canadian Institutes of Health Research

Funding period
CAD 295 K
USD 276 K
Funding amount
Abstract
Bladder cancer is the seventh most common cancer worldwide, the fourth most prevalent cancer in Canada in men, twelfth in women, and has an overall mortality rate of 20 percent. It has the highest lifetime treatment cost per patient of any cancer and yet despite the drivers of cost, high mortality and morbidity, no new therapies have emerged in the past few decades with numerous clinical trials showing no improvement over mitomycin C and Bacillus Calmette Guerin (BCG), the current standard of care. Microtubules are one of the most successful targets in cancer therapy and the recent phase I trial of intravesical docetaxel for the treatment of nonmuscle invasive bladder cancer, refractory to BCG, has shown this to be a promising agent. However, conventional formulations are maintained in the bladder for only two hours and drug exposure rarely lasts beyond the first voiding of urine, resulting in low drug uptake into bladder tissues. There is a clear unmet need for formulations that improve the residence time and penetration of intravesical agents. We have developed a novel polymeric drug delivery platform for the intravesical delivery of docetaxel employing Hyperbranched Polyglycerol (HPG) drug delivery technology. It has demonstrated superior efficacy in proof of concept studies over the commercial Taxotere formulation and provides enhanced drug retention and tissue penetration characteristics in in vivo and ex vivo studies. The aim of this project is to complete early stage preclinical development of a novel therapy for bladder cancer enabling our funding partner, CDRD Ventures Inc. (CVI) to create a private company to move the technology towards clinical studies. A Canadian spinoff company translating UBC and CDRD IP will improve the health of Canadians and others worldwide, while bringing further international recognition and investment to both Canadian innovation and the Canadian biotechnology industry.
Similar projects All >
Sorted by: Start Date
Project list item
Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Canadian Institutes of Health Research to Wassim Kassouf, Jonathan David Spicer, Ciriaco A. Piccirillo

USD 138,878
2020 - 2025
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

National Cancer Institute to NINA BHARDWAJ, JUN ZHU, MATTHEW GALSKY

USD 703,400
2020 - 2025
Project list item
SGLT-2 Inhibitors and Early Bladder Cancer Events: An International Multi-Centre Study

Canadian Institutes of Health Research to Laurent Azoulay, Elisabetta Patorno, Oriana Hoi Yun Yu, Sebastian Schneeweiss, Robert William Platt, Blanaid Hicks, Lysanne Campeau, Devin Abrahami

USD 88,269
2020 - 2022
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Roles of epigenetic regulators in bladder cancer progression

University of California - Cancer Research Coordinating Committee to Zhu Wang

USD 74,960
2020 - 2020

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Bioengineering

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Clinical Trials and Supportive Activities

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    5.1 Pharmaceuticals

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science